LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomérieux Launches Free Mobile App to Aid Clinicians in Emergency and Critical Care Diagnostics

By LabMedica International staff writers
Posted on 04 Mar 2022
Image: MYACUTECASE (Photo courtesy of bioMérieux)
Image: MYACUTECASE (Photo courtesy of bioMérieux)

A free mobile application aims to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics. In hospitals, particularly for emergency cases, diagnostic options can be limited for patients with acute and complex pathologies. Clinicians need to rapidly and accurately assess and identify the correct therapeutic protocol for each patient. With the vast array of biomarkers available today, interpretation can be challenging but crucial to optimize patient care and help save lives. For correct interpretation of a particular in vitro diagnostics (IVD) test, it is of paramount importance to align the medical diagnostic and management decisions with corresponding guidelines, expert recommendations and best practices.

bioMérieux (Marcy-l'Étoile, France) has developed the first of a kind mobile application, MYACUTECASE that serves as an aid in the interpretation of VIDAS emergency and critical care biomarker tests. The first version of bioMérieux’s easy-to-use mobile application addresses four emergency and critical care assays, namely VIDAS D-Dimer Exclusion II, VIDAS NT-proBNP2, VIDAS B.R.A.H.M.S PCT, and VIDAS High sensitive Troponin I.

Through the application’s educational material, hospitals will be able to support continuous healthcare education through on-demand high medical value content regarding targeted disease states, corresponding diagnostic pathways, relevant biomarkers and their use in various situations. It combines within the same digital tool the entire information that one finds in the test’s package insert, the information brochure, various peer-reviewed national and international guidelines, and other relevant material.

MYACUTECASETM is registered as IVD software and has been co-developed with experts and target users. More than 20 clinicians were involved in designing and approving MYACUTECASE. The application is now available on Apple App Store for free, both in French and in English, and it is planned to evolve by including other test parameters or languages. In the future it will also be compatible with other OS such as Android.

“With MYACUTECASE, our goal is to help clinicians choose the right biomarker tests to order for a particular patient and facilitate the interpretation of results,” said Mark Miller, Executive Vice President, Chief Medical Officer. “A rapid and easy access to testing and disease information, expert guidelines and best practices will allow them to improve patient care and potentially to save lives.”

“MYACUTECASE is a very innovative application that will help labs and clinicians working together but also clinicians better interpreting insights from VIDAS emergency testing,” added Pierre Boulud, Chief Operating Officer, Clinical Operations. “Our data insight solutions are a strategic component of our offering. They bring unique opportunities to leverage the quality of diagnostics to enhance its medical value for the benefit of patients.”

Related Links:
bioMérieux 

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Sample Transportation System
Tempus1800 Necto

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more